Ownership
Private
Employees
~50
Therapeutic Areas
Oncology
Stage
Preclinical
Modalities
Small molecule

Hercules Pharmaceuticals General Information

Developing AhR inhibitors for cancer immunotherapy, showing promising results in early studies. The therapy aims to activate the immune system by inhibiting AhR in cancers with high AhR expression.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Leiden,
Netherlands

Drug Pipeline

Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Hercules Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Boston University

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Hercules Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Hercules Pharmaceuticals's complete valuation and funding history, request access »

Hercules Pharmaceuticals Investors

UNIIQ
Investor Type: Venture Capital
Holding: Minority
Eurostars Programme
Investor Type: Venture Capital
Holding: Minority
Pharma Connect Capital grant/SNN regional support
Investor Type: Venture Capital
Holding: Minority